The US Food and Drug Administration (FDA) has approved Mylan Pharmaceuticals' Abbreviated New Drug Application (ANDA) for modafinil tablets USP,100 mg and 200 mg. This product is the generic version of Cephalon's Provigil tablets and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift work disorder.

Mylan CEO Heather Bresch commented: "Mylan is pleased to bring a generic version of Provigil tablets to the US market prior to the expiration of the first-filer's 180-day marketing exclusivity period. This launch represents Mylan's continued commitment to expanding access to high quality, more affordable medicine, and we are pleased to do our part in helping to meet patients' unmet needs."

Modafinil tablets, 100 mg and 200 mg, had US sales of approximately $1.3 billion for the 12 months ending June 30, 2012, according to IMS Health. Mylan is launching this product immediately.

Currently, Mylan has 166 ANDAs pending FDA approval representing $78.4 billion in annual sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $25.1 billion in annual brand sales, for the 12 months ending Dec. 31, 2011, according to IMS Health.

Mylan Pharmaceuticals, a subsidiary Mylan Inc., is a global pharmaceutical company committed to setting new standards in health care.